Agenus Inc
AGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$139.5M
Close$
$-6.07
219.5% downside
Current Fair Value
219.5% downsideOvervalued by 219.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $139.50 Million |
|---|---|
| Enterprise Value | $408.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 1.55 |
| Outstanding Shares | 37,941,000 |
Return
| Return on Equity | -29.20% |
|---|---|
| Return on Assets | 34.65% |
| Return on Invested Capital | -143.05% |
Valuation & Multiples
| P/E Ratio | 1.94 |
|---|---|
| PEG | -0.76 |
| Price to Sales | 1.69 |
| Price to Book Ratio | -0.73 |
| Enterprise Value to Revenue | 3.3 |
| Enterprise Value to EBIT | 4.55 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.74 |
| Debt to Equity | -1.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$2.10
Average shareholder expectationRevenue Estimate
$129.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$34.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 41.83% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.10%▼ 30.87% |
|---|---|
| Total Invested | $118,958▼ 99.61% |
| Investors Holding | 3▼ 87.00% |
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...